Systemic treatment of osteogenesis imperfecta.
Seventy percent of published articles on the medical treatment of osteogenesis imperfecta have claimed beneficial results for 20 different agents. This observation conflicts with current practice since no form of treatment has been accepted as effective in dealing with the disease. A few medications or combinations of medications hold some promise, but adequate documentation must be availble before they can be accurately assessed. It is essential that the practitioner maintain a high degree of skepticism toward positive results of treatment regardless of the source. At the present time, no agent is available which will be of any value to the practitioner who has a patient with osteogenesis imperfecta.
D000293:Adolescent; D000367:Age Factors; D000728:Androgens / Q000627:therapeutic use; D002116:Calcitonin / Q000627:therapeutic use; D004032:Diet; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D050723:Fractures, Bone / Q000150:complications; D006801:Humans; D008903:Minerals / Q000627:therapeutic use; D010013:Osteogenesis Imperfecta / Q000150:complications / Q000151:congenital / Q000188:drug therapy*; D014807:Vitamin D / Q000627:therapeutic use
D000728:Androgens; D004967:Estrogens; D008903:Minerals; D014807:Vitamin D; D002116:Calcitonin